Pfizer Inc. $PFE Stock Bought by Soltis Investment Advisors LLC

Key Points

• Soltis Investment Advisors increased its Pfizer stake by 276.7% in the third quarter, ending with 101,626 shares valued at approximately $2.9 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported positive developments across its pipeline, including a successful Phase 3 ELREXFIO trial, expanded TALZENNA and XTANDI use, encouraging lorlatinib data, and a new Alzheimer’s drug trial. Investors remain focused on whether these products can offset declining COVID-related revenue.
• Analysts have a consensus “Hold” rating and an average price target of $28.65, below the reported $30.48 share price. Pfizer’s $0.43 quarterly dividend offers a 5.6% yield, but its payout ratio of 226.32% raises concerns about dividend sustainability.

Soltis Investment Advisors LLC grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 276.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,626 shares of the biopharmaceutical company's stock after acquiring an additional 74,645 shares during the period. Soltis Investment Advisors LLC's holdings in Pfizer were worth $2,898,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Bank of America Corp DE purchased a new stake in shares of Pfizer in the second quarter valued at approximately $1,049,602,000. BlackRock Inc. increased its holdings in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares during the period. Nykredit A S purchased a new position in Pfizer during the 2nd quarter worth $205,774,000. Assenagon Asset Management S.A. raised its position in Pfizer by 96.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company's stock valued at $286,609,000 after purchasing an additional 5,829,204 shares in the last quarter. Finally, State Street Corp raised its position in Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Analysts Set New Price Targets

Several brokerages have weighed in on PFE. Bank of America lowered their target price on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Scotiabank raised their price target on Pfizer from $30.00 to $33.00 and gave the company an "outperform" rating in a research note on Tuesday, October 6th. BMO Capital Markets decreased their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, July 13th. Weiss Ratings upgraded Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 31st. Finally, HSBC upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research note on Thursday, September 10th. Five research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $28.65.

Pfizer Stock Performance

Shares of PFE stock opened at $30.48 on Friday. The firm has a market cap of $173.73 billion, a price-to-earnings ratio of 40.11, a PEG ratio of 2.03 and a beta of 0.32. The company's 50 day moving average is $28.55 and its 200 day moving average is $26.79. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $30.67.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's payout ratio is presently 226.32%.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.